Dhampur Bio Organics Q2 FY27 standalone revenue Rs 665.5 cr; PAT Rs 26.6 cr
Results$DBOL

Dhampur Bio Organics Q2 FY27 standalone revenue Rs 665.5 cr; PAT Rs 26.6 cr

Dhampur Bio Organics’ standalone revenue (net of excise) rose to Rs 665.50 cr in Q2 FY27, with PAT at Rs 26.60 cr versus a loss in Q2 FY26.

Dhampur Bio Organics Ltd
Dhampur Bio Organics LtdReviewed and published by · How we report
3 min read
dhampur bio organicsq2 fy27 resultssugarearningspat
ShareWhatsAppXLinkedIn

Key takeaways

  • Rs 665.50 cr revenue (net of excise) in Q2 FY2027 vs Rs 537.30 cr in Q2 FY2026.
  • EBITDA rose to Rs 60.00 cr in Q2 FY2027 from Rs 13.00 cr in Q2 FY2026.
  • PBT was Rs 39.20 cr in Q2 FY2027 vs Rs (12.20) cr in Q2 FY2026.
  • PAT stood at Rs 26.60 cr in Q2 FY2027 vs Rs (15.50) cr in Q2 FY2026.
  • Basic EPS improved to Rs 4.1 in Q2 FY2027 from Rs (2.34) in Q2 FY2026.

Q2 FY27 · standalone

MetricSep 2026Sep 2025Change
RevenueRs 665.50 crRs 537.30 cr+23.9%
PATRs 26.60 crRs (15.50) crturned positive

As reported in the filing. Figures are transcribed, not computed.

What the numbers show

  • Net margin was 4.00% of revenue, up 688 bps from -2.88%.

• Revenue (Net of Excise): Rs 665.50 cr in Q2 FY2027 vs Rs 537.30 cr in Q2 FY2026, as per the profit & loss statement – Q2FY27 (standalone).

• EBITDA: Rs 60.00 cr in Q2 FY2027 vs Rs 13.00 cr in Q2 FY2026, according to the statement of financial results in the investor presentation.

• EBITDA Margin (%): 9.02% in Q2 FY2027 vs 2.41% in Q2 FY2026, as reported in the same table.

• Depreciation & Amortization: Rs 13.00 cr in Q2 FY2027 vs Rs 12.40 cr in Q2 FY2026.

• EBIT: Rs 47.10 cr in Q2 FY2027 vs Rs 0.50 cr in Q2 FY2026.

• EBIT Margin (%): 7.08% in Q2 FY2027 vs 0.10% in Q2 FY2026.

• Finance Cost: Rs 7.90 cr in Q2 FY2027 vs Rs 12.80 cr in Q2 FY2026.

• PBT: Rs 39.20 cr in Q2 FY2027 vs Rs (12.20) cr in Q2 FY2026.

• PBT Margin (%): 5.89% in Q2 FY2027 vs (2.28%) in Q2 FY2026.

• PAT from Continuing Operations: Rs 26.60 cr in Q2 FY2027 vs Rs (8.30) cr in Q2 FY2026.

• PAT from Discontinuing Operations: Rs - crores in Q2 FY2027 vs Rs (7.20) cr in Q2 FY2026.

• PAT (Total): Rs 26.60 cr in Q2 FY2027 vs Rs (15.50) cr in Q2 FY2026.

• PAT Margin (%): 4.00% in Q2 FY2027 vs (2.89%) in Q2 FY2026.

• Basic EPS (Rs/share): Rs 4.1 in Q2 FY2027 vs Rs (2.34) in Q2 FY2026.

According to the profit & loss statement – Q2FY27 in the investor presentation (standalone financials), Dhampur Bio Organics reported revenue (net of excise) of Rs 665.50 cr for Q2 FY2027, up from Rs 537.30 cr in the corresponding quarter of the previous year. EBITDA increased to Rs 60.00 cr from Rs 13.00 cr, with the company also disclosing an EBITDA Margin (%) of 9.02% compared with 2.41% a year earlier.

Depreciation & Amortization for the quarter was Rs 13.00 cr versus Rs 12.40 cr in Q2 FY2026, leading to EBIT of Rs 47.10 cr against Rs 0.50 cr in the year-ago quarter. The EBIT Margin (%) was reported at 7.08% compared with 0.10% in Q2 FY2026. Finance Cost declined to Rs 7.90 cr from Rs 12.80 cr, and PBT turned positive at Rs 39.20 cr versus a loss of Rs (12.20) cr in the same quarter last year, with the PBT Margin (%) moving to 5.89% from (2.28%).

PAT from Continuing Operations came in at Rs 26.60 cr in Q2 FY2027 compared with a loss of Rs (8.30) cr in Q2 FY2026. PAT from Discontinuing Operations was reported as Rs - crores for Q2 FY2027 versus Rs (7.20) cr a year earlier. Overall PAT stood at Rs 26.60 cr in Q2 FY2027 against a loss of Rs (15.50) cr in Q2 FY2026, with the PAT Margin (%) at 4.00% versus (2.89%). Basic EPS (Rs/share) improved to Rs 4.1 from Rs (2.34) over the same period, as disclosed in the statement of financial results.

Track Dhampur Bio Organics Ltd

Cruxal reads every Dhampur Bio Organics Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.

Get every filing that moves a stock

One email before the open, with the day's filings that actually shifted a price — the number, the source document and what the market did with it. Free, and you can unsubscribe from any issue.

Cruxal publishes market coverage for information only. Nothing here is investment advice.